Ovarian function after successful bone marrow transplantation in postmenarcheal females.
Ovarian function was followed serially in a group of six postmenarcheal females after successful bone marrow transplantation (BMT). The patients were between 13 9/12 and 22 6/12 (median 16 5/12) years of age at the time of BMT and were followed a median of 20 months (range 17-45 months) posttransplantation. Two subjects received short-term high-dose cyclophosphamide combined with single-dose total lymphoid irradiation (Group I), whereas the remaining four were treated with short-term, high-dose chemotherapy plus single-dose total body irradiation (Group II). Group II subjects also received combination chemotherapy prior to BMT. One subject from Group I continues to have regular menses and normal gonadotropin levels, 36 months post-BMT. The remaining five patients have demonstrated persistently elevated plasma concentrations of LH and FSH over a 17- to 45-month period of time. None of the four patients in Group II has menstruated since undergoing BMT. We conclude that single-dose radiation combined with short-term, high-dose chemotherapy results in profound ovarian damage in the majority of young women undergoing BMT.
D000293:Adolescent; D000741:Anemia, Aplastic / Q000628:therapy; D000970:Antineoplastic Agents / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D002648:Child; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007938:Leukemia / Q000628:therapy; D007986:Luteinizing Hormone / Q000097:blood; D008223:Lymphoma / Q000628:therapy; D008572:Menarche; D008599:Menstruation Disturbances / Q000209:etiology; D010050:Ovarian Function Tests; D010053:Ovary / Q000503:physiopathology*; D011878:Radiotherapy / Q000009:adverse effects
D000970:Antineoplastic Agents; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone